The scientist’s investigation covers issues in Immunology, Cancer research, Lymphokine-activated killer cell, Cell biology and Interferon. Her biological study spans a wide range of topics, including Haematopoiesis and Peripheral blood mononuclear cell. Her Natural killer T cell research extends to Lymphokine-activated killer cell, which is thematically connected.
Her Cell biology research incorporates themes from Perforin, Natural killer cell and Janus kinase 3. Her Interferon research incorporates elements of T lymphocyte and Interferon gamma. Her research integrates issues of Neoplasm and Serology, Antibody in her study of Virology.
Julie Y. Djeu focuses on Immunology, Molecular biology, Cancer research, Lymphokine-activated killer cell and Cytokine. Immunology and Cytotoxic T cell are frequently intertwined in her study. The various areas that Julie Y. Djeu examines in her Cancer research study include Apoptosis, Protein kinase B, Signal transduction, Prostate cancer and Immunotherapy.
Her Lymphokine-activated killer cell study combines topics in areas such as Natural killer T cell, Natural killer cell, Cell biology and Monocyte. Her Cytokine study combines topics from a wide range of disciplines, such as Tumor necrosis factor alpha, Granulocyte and Microbiology, Candida albicans. As part of the same scientific family, she usually focuses on Virology, concentrating on Serology and intersecting with Neoplasm.
Her primary areas of investigation include Cancer research, Immunology, Immune system, Cancer and Cell biology. Her Cancer research research is multidisciplinary, incorporating perspectives in Cell culture, Apoptosis, T cell, Prostate cancer and Radiation therapy. Her Immunology research includes themes of Haematopoiesis, Internal medicine and Myeloid-derived Suppressor Cell.
Her Cell biology research integrates issues from Receptor, Immune receptor, Large Granular Lymphocytes and Lymphokine-activated killer cell. Her work deals with themes such as Natural killer T cell and Cytotoxicity, which intersect with Lymphokine-activated killer cell. Her study looks at the intersection of Lymphocyte and topics like Cytotoxic T cell with Molecular biology and Calcium flux.
Her primary scientific interests are in Immunology, Cancer research, Clusterin, Leukemia and Bone marrow. She combines subjects such as Internal medicine, Stem cell and Myeloid-derived Suppressor Cell with her study of Immunology. Her study in Cancer research is interdisciplinary in nature, drawing from both Cancer, Cytoprotection, Apoptosis, Protein kinase B and Transfection.
Her studies deal with areas such as Translational research, Protein stabilization, Computational biology and Bioinformatics as well as Clusterin. Her Leukemia study integrates concerns from other disciplines, such as Immunosurveillance, Myeloid, Receptor, NKG2D and Myeloid leukemia. Her research in Bone marrow intersects with topics in Phosphatase, Ubiquitin, Mdm2 and Hyperphosphorylation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Natural Killer Cells: Characteristics and Regulation of Activity
Ronald B. Herberman;Ronald B. Herberman;Ronald B. Herberman;Julie Y. Djeu;Julie Y. Djeu;Julie Y. Djeu;H. David Kay;H. David Kay;H. David Kay;John R. Ortaldo;John R. Ortaldo;John R. Ortaldo.
Immunological Reviews (1979)
Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells
Elizabeth Ann Grimm;Keith M. Ramsey;Amitabha Mazumder;Debra J. Wilson.
Journal of Experimental Medicine (1983)
Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.
A H Rook;H Masur;H C Lane;W Frederick.
Journal of Clinical Investigation (1983)
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Krithika N. Kodumudi;Karrune Woan;Danielle L. Gilvary;Eva Sahakian.
Clinical Cancer Research (2010)
Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells.
Kun Jiang;Bin Zhong;Danielle L. Gilvary;Brian C. Corliss.
Nature Immunology (2000)
Circulating activated suppressor T lymphocytes in aplastic anemia.
Nicholas C. Zoumbos;Pedro Gascón;Julie Y. Djeu;Stephen R. Trost.
The New England Journal of Medicine (1985)
Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo.
Nicholas C. Zoumbos;Pedro Gascon;Julie Y. Djeu;Neal S. Young.
Proceedings of the National Academy of Sciences of the United States of America (1985)
Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-gamma and tumor necrosis factor.
J Y Djeu;D K Blanchard;D Halkias;H Friedman.
Journal of Immunology (1986)
Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer
Kong W;He L;Richards Ej;Challa S.
Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein.
James Turkson;Tammy Bowman;Jalila Adnane;Yi Zhang.
Molecular and Cellular Biology (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: